This is the information available about Claritin D use in pregnancy. The risk verse benefit needs to be determined.
Loratadine / pseudoephedrine Pregnancy Warnings
Loratadine-pseudoephedrine has not been assigned to a pregnancy category by the FDA. Animal studies have failed to reveal evidence of teratogenicity. There are no controlled data in human pregnancy. Loratadine-pseudoephedrine is only recommended for use during pregnancy when benefit outweighs risk.
A case controlled surveillance study reported an elevated relative risk (3.2) of gastroschisis with first-trimester pseudoephedrine use in 76 cases. The relative risk for other drugs was 1.6 for salicylates, 1.7 for acetaminophen, 1.3 for ibuprofen, and 1.5 for phenylpropanolamine (not significant). The authors hypothesized vascular disruption was the etiology of gastroschisis. A second group of 416 infants with heterogenous defects suspected to have a vascular etiology was studied. There was no increased risk associated with the use of salicylates, ibuprofen, pseudoephedrine, phenylpropanolamine, and other decongestants. These data require independent confirmation. In a review of 229,101 deliveries to Michigan Medicaid patients, 940 first-trimester exposures to pseudoephedrine were recorded and 191 exposures any time during pregnancy. A total of 37 birth defects were reported with first trimester exposure (40 expected) and included (observed/expected) 3/9 cardiovascular defects, 2 oral clefts, and 3/2 polydactyly. These researchers reviewed nine cases of abdominal wall defects in the 1980 to 1983 Medicaid data. Seven of the nine cases occurred in 3752 pseudoephedrine exposed pregnancies, providing a relative risk of 1.8. Only one case was a surgically treated abdominal wall defect (written communication, Franz Rosa, MD, Food and Drug Administration, 1994). The Collaborative Perinatal Project monitored 50,282 mother-child pairs. Only 39 first-trimester exposures to pseudoephedrine were recorded, with one birth defect observed. For use any time during pregnancy, 194 exposure were recorded with 3 birth defects observed (3.22 expected). The effect of pseudoephedrine on uterine and fetal blood flow was studied in 12 healthy pregnant women between 26 and 40 weeks gestation. Following a single 60 mg dose of pseudoephedrine, no significant effect was seen on fetal heart rate, uterine blood flow, or fetal aortic blood flow. There are no other data on the use of loratadine during pregnancy.
Search for questions
Still looking for answers? Try searching for what you seek or ask your own question.
Posted 12 Jan 2010 • 1 answer
Posted 18 Sep 2010 • 1 answer
Posted 17 Oct 2010 • 1 answer
Posted 25 Nov 2013 • 1 answer
Posted 14 Jan 2014 • 2 answers